Merck and Moderna report positive late-stage melanoma vaccine results, adding to 2026 cancer breakthrough year

Merck and Moderna announced that their personalized mRNA neoantigen vaccine achieved positive outcomes in a late-stage trial for melanoma patients. The data suggest the vaccine can stimulate an immune response that translates into clinical benefit.

The announcement follows earlier excitement this year over Revolution Medicines' KRAS‑targeted drug for pancreatic cancer, which also showed promising results. Together, these developments are being described as a landmark year for cancer therapeutics.

Analysts see the successes as evidence that both mRNA‑based approaches and precision‑targeted small molecules are maturing, potentially expanding treatment options and attracting investment across the oncology sector.